A 13-amino-acid synthetic analog of alpha-MSH (afamelanotide) with enhanced MC1R selectivity and metabolic stability. Melanotan I stimulates eumelanin production in melanocytes through MC1R-mediated cAMP/PKA signaling, providing photoprotection independent of UV exposure. FDA-approved as Scenesse (implant) for erythropoietic protoporphyria (EPP) — a rare photosensitivity disorder where patients cannot tolerate sunlight.
Research Profile
Structure13 amino acids (~1,646 Da) — [Nle⁴, D-Phe⁷]-α-MSH analog
TargetsMC1R (melanocortin-1 receptor) — selective
Research FocusEumelanin biosynthesis, photoprotection, vitiligo, skin cancer prevention models
ReconstitutionBacteriostatic water — 1 mg/mL (research SC form)
Stability21 days at 2–8°C
Key distinction: MC1R-selective melanocortin agonist — stimulates photoprotective eumelanin without significant MC3R/MC4R activity. FDA-approved (Scenesse) for EPP as a sustained-release implant.
Scientific Evidence
Published Research
[1]
Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. NEJM 2015;373:48-59 — PubMed 26132941
[2]
Dorr RT et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004;140:827-835 — PubMed 15262693
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.